GIPR and obesity disorder: Indeed, similarly to long-acting GIPR agonist (LAGIPRA), tirzepatide favoured similar protection from obesity and insulin resistance, together with increased catabolism of glucose, lipids, and branched-chain amino acids (BCAA) in BAT.